

## Special Issue

# Functional Genomics, Pharmacogenomics in Human Disease

### Message from the Guest Editor

High-tech genetic research on human genome has identified vast amount of genetic variants and the number continues to increase. Functional information on the genetic variants is critical for justifying its clinical use for personalized medicine. Pharmacogenomics is becoming important in almost all field of medicine, since more patients are having beneficial effects by genotype analysis. Aim of the special issue is to provide explanations for individual susceptibility to drug toxicities, drug resistances, and drug sensitivities. Also include the implication of genetic variants to adverse drug reactions, drug resistances, and disease susceptibilities. Suitable paper includes new research, review, and updated overview of interpretation and application of genetic polymorphism. Authors are encouraged to present functional information to support the observation of drug response or disease sensitivity. Examples of suitable topics include pharmacogenomics with human diseases or drugs, such as cardiovascular diseases, psychiatry diseases, gastrointestinal diseases, cancers, drug addictions, drug sensitivities, drug resistances, and broad range of adverse drug reactions.

---

### Guest Editor

Dr. Su-Jun Lee

Department of Pharmacology and Pharmacogenomics Research Center, College of Medicine, Inje University, Busan, Republic of Korea

---

### Deadline for manuscript submissions

closed (15 July 2021)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/si/53287](https://mdpi.com/si/53287)

*Journal of Personalized  
Medicine*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm.mdpi.com)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).